A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: The need for a uniform approach

European Heart Journal

Volumn 29, Issue 6, 2008, Pages 816-824

  Pang, Peter S ^a   Cleland, John G F ^b   Teerlink, John R ^c   Collins, Sean P ^d   Lindsell, Christopher J ^d   Sopko, George ^e   Peacock, W Frank ^f   Fonarow, Gregg C ^g   Aldeen, Amer Z ^a   Kirk, J Douglas ^h   Storrow, Alan B ⁱ   Tavares, Miguel ^j   Mebazaa, Alexandre ^k   Roland, Edmond ^l   Massie, Barry M ^c   Maisel, Alan S ^m   Komajda, Michel ^n,o   Filippatos, Gerasimos ^p   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^k HÔPITAL LARIBOISIÈRE   (France)

^l AFSSAPS   (France)

^m UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^p UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

Clinical trials; Dyspnoea; Heart failure

Indexed keywords

ACUTE HEART FAILURE; BODY POSITION; CONSENSUS; DYSPNEA; DYSPNEA SEVERITY SCORE; HEART RATE; HUMAN; LUNG CONGESTION; LUNG EDEMA; MORTALITY; OXYGEN SATURATION; PRIORITY JOURNAL; PROVOCATIVE DYSPNEA ASSESSMENT; REGISTER; REVIEW; SELF EVALUATION; SYMPTOM; THORAX RADIOGRAPHY; VISUAL ANALOG SCALE;

ACUTE DISEASE; AGED; CLINICAL TRIALS AS TOPIC; DYSPNEA; FEMALE; HEART FAILURE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 41149148032     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn048     Document Type: Review

References (37)

1. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216.
2. ADHERE Scientific Advisory Committee. Acute Decompensated Heart Failure National Registry(ADHERE®) Core Module Q1 2006 Final Cumulative National Benchmark Report: Scios, Inc., July 2006.
3. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217-2226.
4. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J 2003;145(Suppl. 2):S26-S33.
5. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-3968.
6. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on clinical investigation of medicinal products for the treatment of cardiac failure, Addendum on acute cardiac failure. London, EMEA, European Medicines Agency, July 29, 2004. Report no. CPMP/EWP/2986/03.
7. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
8. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159:321-340.
9. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
10. Scano G, Ambrosino N. Pathophysiology of dyspnea. Lung 2002;180:131-148.
11. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990;142:1009-1014.
12. Elliott MW, Adams L, Cockcroft A, MacRae KD, Murphy K, Guz A. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis 1991;144:826-832.
13. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006;119(Suppl. 1):S3-S10.
14. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-888.
15. Mahdyoon H, Klein R, Eyler W, Lakier JB, Chakko SC, Gheorghiade M. Radiographic pulmonary congestion in end-stage congestive heart failure. Am J Cardiol 1989;63:625-627.
16. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004;148:43-51.
17. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
18. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L. Eurz survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-2736.
19. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
20. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 2006;296:1465-1466.
21. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491.
22. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-1343.
23. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
24. Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol 2005;96:59G-67G.
25. Teerlink JR, Massie B, Cleland J, D T, for the RITZ-1 Investiagators. A double-blind, parallel-group, multi-center, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure. (Abstract). Circulation 2001;104:II-526.
26. Coletta A, Cleland J. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001;3:747-750.
27. Packer M. REVIVE II:Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure (Abstract). American Heart Association Scientific Sessions 2005 Late Breaking Clinical Trials II. Dallas, TX 13-16 November 2005.
28. Yancy CW. Climbing the mountain of acute decompensated heart failure: the EVEREST Trials. JAMA 2007;297:1374-1376.
29. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005;150:46-53.
30. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-832.
31. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
32. Peacock WF. Initial results from the PROACTION study. J Emerg Med 2006;31:435-436.
33. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006;4:70.
34. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891.
35. Teerlink J, Thakkar R, Salon J, Huang B, Padley RJ. Patient self-assessments of heart failure status using either categorical or continuous scales were highly correlated in REVIVE I and II. Eur J Heart Fail 2007;6:103-104.
36. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42:140-147.
37. Cuffe MS, Califf RM, Adams KF Jr., Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Jama. 2002;287:1541-1547.